Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tissueblue

(brilliant blue G)

Small molecule

DDutch Society of Physicians for Pulmonology and Tuberculosis

0

Indications

2

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery

Terminated·AAsociación para Evitar la Ceguera en México·Phase 3·NCT01820520·22 enrolled

Macular Hole1 trial

Internal Limiting Membrane Peeling-reposition to Treat Idiopathic Macular Holes

Completed·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT03020459·30 enrolled

Regulatory

FDA Approval Timeline[3]

Dec 20, 2019

TISSUEBLUE

NDA NDA209569

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for brilliant blue G. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — brilliant blue G compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA209569). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Dutch Society of Physicians for Pulmonology and Tuberculosis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: DDutch Society of Physicians for Pulmonology and Tuberculosis

Related News